Xenon Pharmaceuticals: Azetukalner Nears Late-Stage Development in Neurological Therapeutics
We at Xenon Pharmaceuticals focus on new treatments for brain disorders. Our main drug, azetukalner, opens certain channels in the brain. It targets epilepsy and depression. This drug moves through final tests. These tests check if it works well for patients. We see strong results so far. The market for brain treatments stands at 35…